Market Valuation | Analysts view GBIO's below-cash stock price as fair, reflecting sector uncertainties. Price targets unavailable, but stock shows recent 56% surge despite yearly decline |
T Cell Targeting Tech | Delve into GBIO's innovative ctLNP technology for siRNA delivery to T cells, potentially addressing undruggable targets in immune and inflammatory diseases |
Strategic Overhaul | Explore GBIO's restructuring efforts, including potential asset sales and partnerships, aimed at extending its financial runway beyond current projections |
Biotech at Crossroads | Generation Bio faces pivotal moment with ctLNP technology, balancing innovation against financial constraints in a competitive biotech landscape |
Metrics to compare | GBIO | Peers Peers - average of corresponding metrics from companies closely matching GBIO: | Sector Sector - Average of metrics from a broad group of related sector companies | Relationship RelationshipGBIOPeersSector |
|---|---|---|---|---|
P/E Ratio | 0.0x | 0.0x | −0.2x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price / Book | 0.0x | 0.0x | 2.6x | |
Price / LTM Sales | 0.0x | 0.0x | 2.8x | |
Upside (Analyst Target) | - | 0.0% | 65.5% | |
Fair Value Upside | Unlock | 0.0% | 8.9% | Unlock |